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Introduction: The prevalence of neuropathic lesions in young patients with type 1
diabetes mellitus (T1DM) at the time of transition from pediatric care to adult-oriented
diabetes care is poorly studied. A comparative study with healthy volunteers to assess the
possible neuropathic condition of this special population and to identify the potential early
screening needs has not been performed yet. The results may provide important feedback
to pediatric diabetes care and a remarkable baseline reference point for further follow up in
adult diabetes care.
Patients and Methods: Twenty-nine young patients with T1DM [age: 22.4 ± 2.9 years;
HbA1c: 8.5 ± 2.1%, diabetes duration: 12.2 ± 5.8 years; (mean ± SD)] and 30 healthy
volunteers (age: 21.5 ± 1.6 years; HbA1c: 5.3 ± 0.3%) were involved in the study.
Autonomic function was assessed by standard cardiovascular reflex tests. Complex
peripheral neuropathic testing was performed by Neurometer®, Neuropad®-test,
Tiptherm®, Monofilament®, and Rydel-Seiffer tuning fork tests.
Results: T1DM patients had significantly higher diastolic blood pressure than controls
(80 ± 9 vs. 74 ± 8mmHg, p < 0.01), but there was no significant difference in systolic blood
pressure (127 ± 26 vs. 121 ± 13 mmHg). Cardiovascular reflex tests had not revealed any
significant differences between the T1DM patients and controls. No significant differences
with Neurometer®, Neuropad®-test, and Monofilament® were detected between the two
groups. The vibrational sensing on the radius on both sides was significantly impaired in
the T1DM group compared to the controls with Rydel-Seiffer tuning fork test (right: 7.5 ±
1.0 vs. 7.9 ± 0.3; left: 7.5 ± 0.9 vs. 7.9 ± 0.3, p < 0.05). The Tiptherm®-test also identified an.org August 2021 | Volume 12 | Article 7199531
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Frontiers in Endocrinology | www.frontiersisignificant impairment in T1DM patients (11 sensing failures vs. 1, p < 0.001). In addition,
the neuropathic complaints were significantly more frequently present in the T1DM patient
group than in the controls (9 vs. 0, p < 0.01).
Conclusion: In this young T1DM population, cardiovascular autonomic neuropathy and
cardiac morphological alterations could not be found. However, Rydel-Seiffer tuning fork
and Tiptherm®-tests revealed peripheral sensory neurological impairments in young T1DM
patients at the time of their transition to adult diabetes care.Keywords: health care transition, autonomic neuropathy, type 1 diabetes mellitus, peripheral sensory neuropathy,
blood pressureINTRODUCTION
Diabetes mellitus is one of the most common chronic diseases in
children and adolescents (1, 2), and more than 90% of all
diabetes cases in childhood is type 1 diabetes mellitus (T1DM)
(3). According to a nationwide, population-based Hungarian
database of children and adolescents constructed between 2001
and 2016, the incidence of T1DM in Hungary increased from 16/
100,000 to 23/100,000 and the prevalence of T1DM from 114/
100,000 to 209/100,000 with a male predominance (4). Several
complications, including retinopathy, diabetic kidney disease,
hypertension, cardiovascular autonomic, and peripheral sensory
neuropathy, are associated with the onset of diabetes in
childhood and adolescence and represent a significant burden
for the health care system (5, 6). Diabetic autonomic neuropathy
was defined as an autonomic nervous system disorder in diabetes
or prediabetes after the exclusion of other causes, while diabetic
peripheral neuropathy as a “symmetrical, length-dependent
sensorimotor polyneuropathy attributable to metabolic and
microvessel alterations as a result of chronic hyperglycemia
exposure (diabetes) and cardiovascular risk covariates” (7).
The prevalence of cardiovascular autonomic neuropathy
(CAN) was at least 20% in unselected type 1 and type 2
diabetic patients (8–10) and very low in newly diagnosed
patients with T1DM (11–13). However, the prevalence of CAN
increases substantially with age and diabetes duration both in
T1DM—as at least 30% prevalence was observed in the Diabetes
Control and Complications Trial (DCCT) and the Epidemiology
of Diabetes Interventions and Complications (EDIC) follow-up
study after 20 years of diabetes duration (14)—and in type 2
diabetes mellitus (T2DM) it may be up to 60% after 15 years (8,
13, 15, 16). CAN is a proven risk factor for cardiovascular
morbidity, and its presence causes a 3.65-fold increase in the
relative risk of mortality (8, 10, 12).
Clinical diabetic neuropathy is rarely seen in pediatric
populations; however, subclinical neuropathy (peripheral nerve
function abnormalities without any clinical symptoms) may be
common among adolescents (17–20). In diabetic peripheral
neuropathy (DPN), the dysfunction of the small and/or large
nerve fibers can be seen, and DPN is associated with neuropathic
pain, foot ulceration, gangrene (21). Several studies showed that
the prevalence of DPN was 7–11% in young patients (8–21 years
old) with T1DM (22, 23). Risk factors for DPN in youth withn.org 2T1DM are poor glycemic control, large glycemic variability,
older age, pubertal stage, longer diabetes duration, smoking,
increased diastolic blood pressure, obesity, increased LDL
cholesterol and triglyceride, and lower HDL cholesterol levels
(23–30). Subclinical DPN has been also found in children with
good metabolic control and short diabetes duration, which
suggests an additional role of genetic predisposition (22, 26, 31).
Health care transition (HCT) is a prepared, systematic
process to transfer adolescents and young adults with chronic
diseases from pediatric to adult health care systems (32, 33);
nevertheless, young T1DM patients have to face unique
challenges regarding lifelong diabetes management skills (34).
A recent review by Schmidt et al. (35) showed that the structured,
professionally guided HCT process (planning, transfer
assistance, and integration) resulted in improvements in
disease-specific measures, quality of life, and self-care skills.
Several studies demonstrated an improvement in the glycemic
control of young T1DM patients following a structured
transition program from pediatric to adult diabetes care (36–
39); however, the prevalence of neuropathic lesions in young
patients with T1DM at the time of transition is not known. Our
goal was to assess the possible neuropathic condition of this
special population at the time of transition to define the potential
earlier screening needs. The present results may provide
important feedback to pediatric diabetes care and a remarkable
baseline reference point for further follow-up in adult
diabetes care.MATERIALS AND METHODS
Study Population
Young patients with type 1 diabetes mellitus were eligible for the
study at the time of health care transition from the Department
of Pediatrics and Pediatric Health Center to the Department of
Medicine at the University of Szeged, Hungary. The
measurements were performed from September 2019 to
February 2020 as the first neuropathic status assessment in
adult care. The exclusion criteria included cases of pernicious
anemia, alcoholism, chronic hepatitis, uremia, exposure to
chemical agents, nerve compression, and chemotherapy treatment.
We studied 29 young patients with T1DM [age: 22.4 ± 2.9
years; body mass index (BMI): 22.8 ± 3.0 kg/m2; hemoglobin A1cAugust 2021 | Volume 12 | Article 719953
Vágvölgyi et al. Neuropathy in Transitional Diabetes Care(HbA1c): 8.5 ± 2.1%, mean diabetes duration: 12.2 ± 5.8 years; 13
men/16 women; (mean ± SD)]. A total of 30 age-matched
healthy volunteers (age: 21.5 ± 1.6 years; BMI: 22.3 ± 3.7 kg/




Standard cardiovascular reflex tests were applied (40) to
characterize the presence and severity of the cardiovascular
autonomic neuropathy. These measurements provide a non-
invasive, clinically relevant, reproducible, and standardized
gold-standard determination of autonomic function (13).
During the cardiovascular reflex tests, blood pressure was
measured and six-lead electrocardiograms (ECG) were
continuously recorded. The ECG signals were digitized at 2
kHz sampling rate with a multichannel data acquisition system
(Cardiosys-A01 software, MDE Heidelberg GMBH, Heidelberg,
Germany) connected to a personal computer and stored for later
offline analysis.
Three of these reflex tests record the changes of heart rate
during specific maneuvers: during deep breathing (HRRDB), in
positions of lying then standing up (30/15 ratio), and during and
after a Valsalva maneuver (Valsalva ratio [VR]), while one test
was designed to evaluate systolic blood pressure changes from
lying to standing up (SBPRSU) (8). Those tests aiming to detect
changes in heart rate are used primarily (but not exclusively) for
the assessment of parasympathetic innervation, while the blood
pressure response predominantly reflects the impairment of
sympathetic function (41).
Heart Rate Response to Deep Breathing
Normally, the heart rate is increased during inspiration and
decreased by expiration. The patient was asked to breathe deeply
at the rate of six breaths per minute (5 s in and 5 s out). The
result was expressed as the difference between the measured
maximum and minimum heart rates (beats/min) during the six
breathing cycles.
Heart Rate Response to Standing Up (30/15 Ratio)
Following the position change from lying to standing up, the
heart rate is immediately increased and reaches its maximum at
around the 15th beat after standing up. Then, a relative
bradycardia occurs in healthy subjects with the lowest heart
rate at about the 30th heartbeat. At the start of the test, the patient
was in the supine position while the electrocardiogram was
recorded continuously. Then the patient stood up without
interrupting the recording. The 30/15 ratio was expressed as
the ratio of the longest R-R interval (at around the 30th beat) to
the shortest R-R interval (at around the 15th beat) following
standing up.
Heart Rate Response to Valsalva Maneuver
(Valsalva Ratio)
During the strain period of Valsalva maneuver, the blood
pressure drops and the heart rate rises under physiologic
conditions. Following the procedure, the blood pressure risesFrontiers in Endocrinology | www.frontiersin.org 3and the heart rate slows. The patient was instructed to blow into
a mouthpiece connected to a modified manometer and holding it
at a pressure of 40 mmHg for 15 s, while an electrocardiogram
was recorded continuously. The Valsalva ratio was calculated as
the ratio of the longest R-R interval after the maneuver to the
shortest R-R interval during the procedure.
Systolic Blood Pressure Response From Lying
to Standing Up
In healthy standing subjects, the pooling of blood in the lower
extremities is rapidly corrected by peripheral vasoconstriction.
Severe postural hypotension is a characteristic sign of CAN. This
test is based on blood pressure measurements in lying position
and following standing up. The postural fall in blood pressure is
defined as the difference between systolic blood pressure after 10
min in the supine position and systolic blood pressures at the 1st,
5th, and 10th minutes after standing up. The largest difference
from the systolic pressure in lying is evaluated as the blood
pressure response to standing.
Sensory Nerve Testing
The peripheral sensory function was studied with a
Neurometer® (NM-01/CPT Neurometer, MDE Heidelberg
GmbH, Heidelberg, Germany). This device is suitable for the
quantification of the function of different nerve fibers and
provides a simple, non-invasive, and quantitative measure of
peripheral sensory function (42). Low voltage, electric sine-wave
stimulation was applied transcutaneously, and the current
perception threshold (CPT) values were determined. In our
study, the median and peroneal nerves were tested. The surface
electrodes with 1 cm diameter were placed on the terminal
phalanx of the index finger and the great toe. The electrodes
were fixed only on intact skin surface, while wounds or scars
would have disturbed the peripheral sensations. The amplitude
of the delivered stimuli was between 0.01 and 9.99 mA. The
stimulus was initially increased until a sensation was reported,
then short stimuli (2–5 s) were applied at progressively lower
amplitudes until a minimal threshold for consistent detection
was determined. The CPT values of the upper and lower limbs
were detected at three different stimulating frequencies (2000,
250, 5 Hz). Thus, the thick myelin sheath coated (2 kHz), thin
myelinated (250 Hz), and thin non-myelinated fibers (5 Hz) were
selectively tested.
Neuropad® screening tests (43) were applied by each
candidate to detect the sudomotoric dysfunction, a component
of autonomic neuropathy. The Neuropad® screening test has a
very high sensitivity for the detection of diabetic peripheral
neuropathy (44) and works on the basis that damage to the
nerve fibers in the feet leads not only to a loss of sensation but
also to a malfunctioning sweat system and, in turn, to unusually
dry skin on the feet. The adhesive pad contains the blue salt
anhydrous cobalt II chloride, which reacts and changes to pink
when exposed to water. Patients were allowed a 10-min relaxing
period in definite room temperature (23°C) after they had
removed their shoes and socks. Tests were applied to both
soles at the level of the first through second metatarsal heads.
The time to color change was exactly 10 min after application.August 2021 | Volume 12 | Article 719953
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pending, total blue was evaluated as pathologic.
The 128 Hz Rydel-Seiffer graduated tuning fork test was
applied to evaluate the vibration perception on the distal end
of both radius and hallux on both sides. Interpretation of the
tuning fork results was based on age-dependent normal values
previously published by Martina et al. in 1998 (45). By reading
the result on the scale of 8, 7-8 were defined as normal, 6 as
borderline and 1-5 were evaluated as pathologic which refers to
vibration sensory impairment.
The Semmes-Weinstein Monofilament Test® with a 10 g
monofilament is an objective and simple instrument used in
screening the diabetic foot for loss of protective sensation (46). A
properly calibrated device was used in a quiet and relaxed setting,
and the candidates were not able to see if and where the examiner
applies the filament. Five areas were tested in all cases on the sole:
the hallux, first metatarsus, second metatarsus, and third and
fifth metatarsus heads. Normal sensation in four to five areas was
defined as normal, and normal sensation just in zero to three
areas was evaluated as pathologic.
The Tiptherm® (Tip-Therm GmbH, Düsseldorf, FRG) is a
pen-shaped device with two flat sides used for early diagnosis of
symmetrical polyneuropathy, which measures temperature
sensitivity of the skin (47). This device consists of a plastic
cylinder on one end and a metal cylinder on the other end, with a
diameter of 14 mm each. Each end is applied in a random order
to the skin for 1 s at both hands and feet. The tested person has to
decide which of the two touches feels cooler (48). Candidates
with normal temperature sensation (<10°C) recognize the
different subjective temperature sensation of the two flat
surfaces with Tiptherm® . Candidates with disturbed
temperature sensation (≥10°C) are unable to recognize
the difference.
Neuropathic complaints were assessed by a questionnaire.
Every individual had to make a statement about the presence or
absence of burning, pinprick sensation, numbness, tingling,
hypoesthesia, hyperesthesia, and also about the intensity of
these symptoms and frequency of their occurrence.
Laboratory Data Collection
Fasting venous blood and urine samples were obtained from
patients and controls for the determination of glucose,
hemoglobin A1c, blood urea nitrogen, corrected calcium,
magnesium, sodium, potassium, total protein, albumin,
alkaline phosphatase, urine pH, and for complete lipid, liver,
and blood test profiles. Due to logistical reasons, the collection of
the blood and urine samples was not possible from all patients
and controls.
Echocardiographic Examination
Transthoracic echocardiography has been performed to
determine standard morphological and functional parameters.
The subjects underwent a complete two-dimensional (2D)
transthoracic echocardiographic study using a Toshiba Artida
imaging system (Toshiba Medical Systems, Tokyo, Japan) with a
PST-30SBP phased-array transducer (1–5 MHz). The imagesFrontiers in Endocrinology | www.frontiersin.org 4were obtained in accordance with the recommendations of the
American Society of Echocardiography and the European
Association of Cardiovascular Imaging (49). In all cases, left
ventricular (LV) dimensions, volumes and ejection fraction (EF),
and left atrial (LA) dimensions were measured, and complete 2D
Doppler studies were performed. For purely logistical reasons,
not all T1DM patients and controls were subjected
to echocardiography.
Statistical Analysis
Statistical data were reported as the mean ± SD, with frequencies
(n) and percentages (%), when appropriate. Power analysis for
the study was performed using the software G* Power (Version
3.1.9.2) for power-and-sample size calculation (University of
Düsseldorf, Germany). The calculated sample size was 28,
working with an effect size d = 0.8, alpha as Type I error of
0.05, and a power value of 0.95. Pearson’s chi-squared test or
Fisher’s exact test was used to analyze categorical data, whereas
independent samples t-test was used in case of continuous data.
Statistical tests were performed using R statistical software (R
version 3.6.2, https://www.r-project.org/), and values of p < 0.05
were considered significant.
Ethics Statement
This study was carried out in accordance with the Declaration
of Helsinki (2000) of the World Medical Association and was
approved by the Hungarian Medical Research Council (approval
No. 31891-5/2019/EÜIG). All subjects have given written
informed consent of the study.RESULTS
Clinical and Laboratory Data of Young
Patients With Type 1 Diabetes Mellitus
and Control Subjects
Relevant clinical data of T1DM patients and control subjects are
presented in Table 1. The mean duration of type 1 diabetes was
12.2 ± 5.8 years. Age, weight, height, body mass index, and waist-
to-hip ratio did not differ significantly between control subjects
and young diabetic patients. Mean systolic blood pressure did
not differ significantly between T1DM patients and control
subjects; however, T1DM patients had higher diastolic blood
pressure (80 ± 9 vs. 74 ± 8 mmHg; p = 0.003; Figure 1). At the
time of transition, 10 young T1DM patients received multiple
injections and 19 T1DM patients were on insulin pump therapy.
Only two of the T1DM individuals used continuous glucose
monitoring system (CGMS) both as augmentation for their
insulin pump therapy. After the transition of the T1DM
patients, in the adult-oriented diabetes care in the terms of
multiple injections or pump therapy, none of the patients’
therapy has changed over the past year; however, since then
nine more patients started to use CGMS. Among 29 T1DM
patients, two patients had hypercholesterolemia and six patients
were receiving antihypertensive medications (two were taking
beta blockers, five patients were taking angiotensin-convertingAugust 2021 | Volume 12 | Article 719953
Vágvölgyi et al. Neuropathy in Transitional Diabetes Careenzyme inhibitors, or angiotensin receptor blockers, and three
T1DM patients were taking Ca2+ channel blockers).
Regarding the laboratory parameters, average serum glucose
and HbA1c values were significantly higher in young patients
with type 1 DM compared to healthy controls (Table 2). The
serum magnesium, albumin, and creatinine levels were
significantly lower among T1DM patients, and significantly
higher serum alkaline phosphatase level and eGFR were
detected in the T1DM patients compared to controls
(Table 2). Other laboratory parameters (lipid, liver, and blood
test profile) did not show any significant differences. Two-
dimensional echocardiography has not revealed any significantFrontiers in Endocrinology | www.frontiersin.org 5differences between the two groups. Relevant results are shown
in Table 3.
Cardiovascular Autonomic Function
Standard cardiovascular reflex tests did not indicate any
significant deteriorations in the heart rate responses to deep
breathing (HRRDB), to standing up (30/15 ratio), and to
Valsalva maneuver (Valsalva ratio, VR) or in the systolic blood
pressure response from lying to standing up (SBPRSU) in young
T1DM subjects compared to controls. Autonomic parameters of
young T1DM patients and age-matched control subjects are
shown in Table 4.FIGURE 1 | Mean systolic and diastolic blood pressure in the control group and in type 1 diabetes mellitus (T1DM) patients; **p<0.01 vs. control group; n=30 and
29 individuals in the control and T1DM groups, respectively.TABLE 1 | Clinical data in the study groups.
T1DM patients (n = 29) Controls (n = 30) p value
Diabetes duration (years) 12.2 ± 5.8
Age (years) 22.4 ± 2.9 21.5 ± 1.6 0.115
Weight (kg) 66 ± 13 68 ± 14 0.622
Height (cm) 170 ± 11 174 ± 9 0.113
BMI (kg/m2) 22.8 ± 3.0 22.3 ± 3.7 0.58
Waist-to-hip ratio 0.79 ± 0.07 0.80 ± 0.14 0.891
Male sex (%) 13 (44.8) 12 (40.0) 0.795
Systolic BP (mmHg) 127 ± 25 121 ± 13 0.253
Diastolic BP (mmHg) 80 ± 9 74 ± 8 0.003
Hypertension (%) 6 (20.7) 0 (0.0) 0.011
Hypercholesterolemia (%) 2 (6.9) 0 (0.0) 0.237
Smoking history (%) 9 (31) 4 (13.3) 0.125
Alcohol consumption (%) 8 (27.6) 13 (43.3) 0.279August 2021 | Volume 12 | ArticleThe data are presented as mean ± SD. BMI, body mass index; BP, blood pressure.
The p values in bold are considered significant.719953
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T1DM Patients and Control Subjects
No significant differences were detected with Neurometer®
(Table 5) , Neuropad®-test , and Semmes-Weinstein
Monofilament Test® between the two groups. The vibrational
sensing on the hallux was intact; however, on the radius on both
sides, the vibrational sensing was significantly impaired in the
T1DM group compared to the controls with 128 Hz Rydel-Seiffer
graduated tuning fork test (Figure 2). The Tiptherm®-test
also identified significant temperature sensitivity impairmentFrontiers in Endocrinology | www.frontiersin.org 6in T1DM patients (11 sensing failures vs. 1, p < 0.001).
In addition, the neuropathic complaints were significantly
more frequently present in the T1DM patient group than in
the controls (9 vs. 0, p < 0.01).
Correlations Between Studied Parameters
Diabetes duration (12.2 ± 5.8 years) did not correlate with the
results of the cardiovascular reflex tests (HRRDB: r: −0.225, p =
0.242; 30/15 ratio: r: −0.099, p=0.610; VR: r: −0.138, p=0.475,
SBPRSU: r: 0.128, p=0.507), the HbA1c level (r: 0.163, p=0.458),TABLE 3 | Echocardiographic parameters of the study groups.
T1DM patients (n = 24) Controls (n = 15) p value
Ao (mm) 27.2 ± 3.0 27.2 ± 2.6 0.978
LA (mm) 36.1 ± 4.4 36.7 ± 4.3 0.672
LVEDD (mm) 44.9 ± 4.8 46.7 ± 4.0 0.217
LVESD (mm) 27.9 ± 2.7 28.9 ± 3.5 0.347
IVSd (mm) 8.2 ± 1.0 8.7 ± 0.9 0.099
PW (mm) 8.3 ± 1.1 8.6 ± 0.8 0.261
LVEDV (mL) 100.0 ± 15.5 101.7 ± 23.2 0.800
LVESV (mL) 31.3 ± 6.1 33.1 ± 12.0 0.592
EF (%) 69.4 ± 3.3 68.5 ± 4.3 0.491August 2021 | Volume 12 | ArticleThe data are presented as mean ± SD. Ao, aortic diameter; LA, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVSd,
interventricular septum thickness at end-diastole; PW, left ventricular posterior wall thickness at end-diastole; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-
systolic volume; EF, ejection fraction.TABLE 4 | Results of the cardiovascular autonomic function tests in T1DM patients and controls.
T1DM patients (n = 29) Controls (n = 30) p value
HRRDB (1/min) 32 ± 11 32 ± 9 0.877
30/15 ratio 1.2 ± 0.3 1.1 ± 0.2 0.171
VR 2.2 ± 0.4 2.3 ± 0.3 0.149
SBPRSU (mmHg) 5 ± 6 3 ± 4 0.272The data are presented asmean ± SD. HRRDB, the heart rate response to deep breathing; 30/15 ratio, the heart rate responses to standing up; VR (Valsalva ratio), the heart rate responses
to Valsalva maneuver; SBPRSU, the systolic blood pressure response from lying to standing up.TABLE 2 | Laboratory data in the study groups.
T1DM patients Controls p value
Glucose (mmol/L) 8.4 ± 5.6 (n=18) 4.6 ± 0.6 (n=21) 0.010
HbA1c (%) 8.5 ± 2.1 (n=23) 5.3 ± 0.3 (n=21) <0.001
Blood urea nitrogen (mmol/L) 4.4 ± 1.2 (n=21) 4.3 ± 1.0 (n=22) 0.839
Corrected calcium (mmol/L) 2.3 ± 0.1 (n=13) 2.3 ± 0.1 (n=20) 0.373
Magnesium (mmol/L) 0.8 ± 0.1 (n=11) 0.9 ± 0.1 (n=19) 0.031
Sodium (mmol/L) 139.5 ± 2.2 (n=22) 140.1 ± 3.0 (n=21) 0.431
Potassium (mmol/L) 4.2 ± 0.3 (n=22) 4.3 ± 0.4 (n=21) 0.776
Blood urea nitrogen (mmol/L) 4.4 ± 1.2 (n=21) 4.3 ± 1.0 (n=22) 0.839
Creatinine (mmol/L) 70.7 ± 11.8 (n=21) 79.9 ± 16.6 (n=21) 0.047
eGFR (ml/min/1.73 m2) 113.9 ± 22.0 (n=21) 100.8 ± 17.8 (n=21) 0.040
Cholesterol (mmol/L) 4.7 ± 1.4 (n=22) 4.3 ± 0.9 (n=21) 0.284
Triglyceride (mmol/L) 1.3 ± 1.1 (n=22) 1.0 ± 0.5 (n=21) 0.323
HDL-cholesterol (mmol/L) 1.6 ± 0.3 (n=21) 1.7 ± 0.4 (n=21) 0.491
LDL-cholesterol (mmol/L) 2.2 ± 0.6 (n=17) 2.2 ± 0.7 (n=21) 0.876
Total protein (g/L) 74.1 ± 4.4 (n=14) 73.9 ± 8.5 (n=21) 0.93
Albumin (g/L) 47.7 ± 5.1 (n=19) 51.4 ± 3.3 (n=21) 0.012
Alkaline phosphatase (U/L) 97.8 ± 44.5 (n=21) 63.8 ± 13.8 (n=22) 0.003
Urine pH 6.11 ± 0.8 (n=13) 6.3 ± 0.8 (n=21) 0.493The data are presented as mean ± SD. HbA1c, hemoglobin A1c.
The p values in bold are considered significant.719953
Vágvölgyi et al. Neuropathy in Transitional Diabetes Careor the diastolic blood pressure in T1DM patients (r: 0.309,
p=0.103). In addition, no correlation was found between DM
duration and the results of the vibration testing by Rydel-Seiffer
graduated tuning fork on the right (r: −0.158, p = 0.415) and left
(r: −0.162, p = 0.403) radius.
In the whole observed population (diabetic and control
subjects together), a significant correlation was found between
the HbA1c level and the Valsalva ratio (n = 44, r: −0.483, p =
0.001) and diastolic blood pressure (n = 44, r: 0.352, p = 0.019).
Furthermore, a borderline relationship was found between the
results of the Tiptherm®-tests and the HbA1c level (normalFrontiers in Endocrinology | www.frontiersin.org 7Tiptherm®-tests: n = 35, HbA1c: 6.6 ± 1.9% vs. abnormal
Tiptherm®-tests n = 8, HbA1c: 8.9 ± 2.7%, p = 0.051).DISCUSSION
In this young T1DM population, at the time of transition from
pediatric care to adult-oriented health care system,
cardiovascular autonomic neuropathy or cardiac morphological
disorders were not found. However, besides intact cardiovascular
autonomic and cardiac conditions, peripheral sensoryTABLE 5 | Peripheral sensory function testing by Neurometer® assessing the threshold of the current sensations at the median and peroneal nerves at three different
stimulating frequencies (2000, 250, and 5 Hz).
T1DM patients (n = 29) Controls (n = 30) p value
NM2000 188 ± 93 166 ± 86 0.353
NM250 85 ± 78 56 ± 38 0.078
NM5 50 ± 53 34 ± 28 0.154
NP2000 266 ± 122 270 ± 102 0.898
NP250 158 ± 104 121 ± 67 0.105
NP5 95 ± 76 84 ± 45 0.525August 2021 | Volume 12 | ArticleThe data are presented asmean ± SD. NM2000, current perception threshold (CPT) value of the median nerve at stimulating frequency of 2,000 Hz; NM250, CPT value of the median nerve
at stimulating frequency of 250 Hz; NM5, CPT value of the median nerve at stimulating frequency of 5 Hz; NP2000, CPT value of the peroneal nerve at stimulating frequency of 2,000 Hz;
NP250, CPT value of the peroneal nerve at stimulating frequency of 250 Hz; NP5, CPT value of the peroneal nerve at stimulating frequency of 5 Hz.FIGURE 2 | Peripheral sensory function testing using the 128 Hz Rydel-Seiffer graduated tuning fork on the distal end of right (RR), left (LR) radius, and the right
(RH) and left (LH) hallux in the control group and in type 1 diabetes mellitus (T1DM) patients; *p<0.05 vs. control group; n=30 and 29 individuals in the control and
T1DM groups, respectively.719953
Vágvölgyi et al. Neuropathy in Transitional Diabetes Careneurological impairments were detected with the 128 Hz Rydel-
Seiffer graduated tuning fork test and the Tiptherm®-test, along
with more severe neuropathic complaints in the T1DM patient
group than in the controls.
As poor glycemic control is the most important risk factor for
the development of diabetic peripheral neuropathy (DPN) (21,
24, 28, 50, 51), the relatively low rate of DPN among our studied
young T1DM patients reflects a good pediatric diabetes care.
Early symptoms and signs of peripheral sensory neuropathy
have been reported in 23% of children with T1DM by Barkai
et al. in 1998 (24); therefore, we expected a higher rate of DPN
impairment in our young T1DM group at the time of transition.
However, the DCCT (Diabetes Control Complications Trial)
Research group found in 1993 that intensive insulin therapy
delayed the onset and slowed the progression of DPN by 60%
(52), and thus since then the therapeutic management and
possibilities (insulin pump therapy, continuous blood glucose
monitoring, application of new generation analogue insulins)
have been dramatically improved. In our T1DM population, 19
subjects from 29 were on insulin pump therapy at the time of the
neuropathic assessment, two of them with CGMS. The
therapeutic efficacy in this population was followed by
measuring HbA1c level, as Time-In-Range (TIR) monitoring
was not accessible until the last few years and it is also well-
known that the patients in adolescence are poorly compliant with
a sensor therapy. After the transition of the T1DM patients, in
the adult-oriented diabetes care in the terms of multiple
injections or pump therapy, none of the patients’ therapy has
changed over the past year; however, since then nine more
patients started to use CGMS.
According to ISPAD (International Society for Pediatric and
Adolescent Diabetes) Clinical Practice Consensus Guidelines
released in 2018, the screening for peripheral neuropathy
should start from age 11 years with 2 to 5 years of diabetes
duration and it should be performed annually thereafter (53).
Assessment of sensation, vibration, reflexes in the feet for
peripheral neuropathy, and orthostatic tests, heart rate
variability for cardiac autonomic neuropathy have all been
suggested (53). Our study presented a significantly higher
prevalence of DPN among T1DM subjects compared to
healthy volunteers, and these results confirm a need for early
screening and better risk factor management as soon as possible.
Interestingly, we found reduced vibration sensation in young
T1DM patients in the upper limb and not in the lower limb,
which is a rather unusual finding (Figure 2). The finding of
reduced vibration sensation in young T1DM patients per se is not
surprising as the large-fiber dysfunction appears first in diabetic
length-dependent peripheral neuropathy. However, peripheral
neuropathies may affect different types of nerve fibers to different
degrees, and the usual concept is that sensory nerves in the lower
limb are predominantly affected and symptoms begin at the
terminal of the longest nerves in diabetes mellitus (54). On the
other hand, the proper diagnosis of diabetic peripheral sensory
neuropathy, mostly at the early stages, remains challenging, and
several recent reviews summarize the current approaches and
suggest strategies to further improve diagnostic testing (55, 56).Frontiers in Endocrinology | www.frontiersin.org 8The majority of studies on diabetes consider peripheral
sensorimotor neuropathy of the lower extremities, and only a
few, mostly sensory and motor nerve conduction velocity studies
have examined sensory function in the hands (57–61).
The examination of the vibration perception can be useful to
detect diabetic peripheral sensory neuropathy at an early stage,
and it can be easily assessed by a 128 Hz tuning fork (54).
Normative values of vibration perception thresholds in finger
pulps and metatarsal heads have been published in healthy
children and adolescents (62) and in adults (63). A recent
study by Abraham et al. (64) found impaired vibration
perception both in the fingers and in the toes among patients
with type 1 and type 2 diabetes mellitus; however, the difference
was significant only in the toes compared to healthy controls.
The study by Ising et al. (65) investigated vibration sensation
among children and adolescents with type 1 diabetes, and they
also found that impaired vibrotactile sense was more common in
the foot than in the hand. However, in few cases of this study,
concurrent impaired vibrotactile sense was found in the hand
and one subject presented with impaired vibrotactile sense in the
hand without having impaired sense in the foot at the same time.
Due to the relative paucity of data on this issue, and given the
unusual nature of our present findings on reduced vibration
sensation in the upper but not in the lower limbs in young T1DM
patients, further studies are warranted to confirm and/or extend
these results.
According to recent guidelines (13, 66), it is recommended to
assess cardiovascular autonomic function upon diagnosis in type
2 diabetes and within 5 years of diagnosis in type 1 diabetes
followed by yearly repeated tests. Established risk factors for
CAN are mainly the lack of proper glycemic control in T1DM
and, in addition, dyslipidemia, hypertension, obesity in T2DM.
Furthermore, glycemic variability (67), oxidative stress, aging-
related neuronal dysfunction and death, inflammation, and
genetic biomarkers also play important roles in the
pathogenesis of CAN (10, 13). Therefore, the intensive
glycemic control as early as possible in T1DM is essential to
prevent or delay the development of CAN, and beside glycemic
control, multifactorial interventions (e.g., lifestyle modification,
pharmacological therapy) might be effective in T2DM (13, 14,
68). The EURODIAB IDDM Study and the EURODIAB
Prospective Study clearly prove that apart from glycemic
control, the classic cardiovascular risk factors (high triglyceride
level, body mass index, smoking, and hypertension) are all risk
factors of autonomic neuropathy as well (26, 69).
Two risk factors are common in both T1DM and T2DM: the
lack of proper glycemic control and the duration of diabetes;
however, the most characteristic difference regarding CAN in
T1DM and T2DM is the fact that the signs and symptoms appear
later in T1DM than in T2DM. This is likely due to the longer
duration of the metabolic abnormalities (dysglycemia) and the
cascade of multiple complex mechanisms and pathogenic
pathways that induce oxidative stress and autonomic neuronal
dysfunction in diabetes, which occur already prior to the
diagnosis of T2DM (70–72). The pathogenesis of type 2
diabetes is more complex than in type 1 diabetes, and theAugust 2021 | Volume 12 | Article 719953
Vágvölgyi et al. Neuropathy in Transitional Diabetes Careabovementioned cardiovascular risk factors are much more
frequently present, which explains the higher prevalence of
autonomic neuropathy in type 2 diabetic patients. With a
mean diabetes duration of 12.2 ± 5.8 years in our study group,
CAN would have been definitely expected. The reasons for the
lack of the impairment might be multifactorial, including the
young age, the efficient pediatric diabetes care, and the ideal body
weight of the studied diabetic population achieved by sport.
Among the young T1DM patients, we found significantly
higher comorbidity with hypertension (in six diabetic patients)
with a significantly increased diastolic blood pressure without
detectable cardiac morphologic differences or cardiovascular
autonomic neuropathy compared to controls, and in the whole
observed population (diabetic and control subjects together), a
significant correlation was found between HbA1c level and
diastolic blood pressure. This finding is consistent with
previous studies on diastolic blood pressure in childhood
diabetes (73–75).
It is well-known that hypomagnesemia is common in poorly
controlled and chronically treated diabetic patients (76, 77).
Several previous studies—consistent with our present finding—
demonstrated lower serum magnesium level in young T1DM
patients (78–84). A recent systematic review and meta-analysis
by Rodrigues et al. (85) showed an association between reduced
levels of magnesium and poor glycemic control in patients with
T1DM, potentially contributing to the early development of
cardiovascular complications.
In summary, at the time of transition from pediatric to
adult-oriented health care in this young T1DM population,
cardiovascular autonomic neuropathy and cardiac morphological
differences could not be found. However, peripheral sensory
neurological impairments with several modalities were detected
among young type 1 diabetic patients. The results may provide
important feedback to pediatric diabetes care and a remarkable
baseline reference point for further follow-up in adult diabetes care.LIMITATIONS
Continuous involvement of young T1DM patients following
their entrance to the adult healthcare system and further
enlargement of this specific study population is planned in the
future. In addition, an annual follow-up of the already involvedFrontiers in Endocrinology | www.frontiersin.org 9subjects is designed to estimate the progress of their neuropathic
state. The listed medicines might also have an impact on the test
results. Due to the low number of T1DM patients on oral
antihypertensive therapy, a statistical analysis has not been
feasible to perform yet. The echocardiographic examinations
and the collection of the blood and urine samples due to logistical
reasons were not possible from all the patients and controls.DATA AVAILABILITY STATEMENT
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